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Conclusions: Valsartan 160 mgHCTZ 25 mg is an effective and
well-tolerated therapy in this patient population with possible beneficial
effects on vascular markers.
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24-HOUR AMBULATORY BLOOD-PRESSURE
EFFECTS OF VALSARTAN 
HYDROCHLOROTHIAZIDE COMBINATIONS
COMPARED WITH AMLODIPINE IN HYPERTENSIVE
PATIENTS AT INCREASED CARDIOVASCULAR RISK
Luis M Ruilope, Daniela Heintz, Andrea A Brandao, Pelle Stolt,
Albert Kandra, Massimo Santonastaso, Yasser Khder. Chief
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain; Novartis,
Basel, Switzerland; Hospital Universitario Pedro Ernesto, Rio de
Janeiro, Brazil; Ospedale Civile, Vittorio Veneto, Italy.
In a randomised, double-blind trial, the effects on 24-hr ABP of the
combination valsartan 160 mg od and hydrochlorothiazide (HCTZ) 25 or
12.5 mg during 24 weeks of therapy were compared with the effects of
amlodipine 10 mg monotherapy (group A10) in 474 stage-II hypertensive
patients with additional cardiovascular risk factors. After a two-week
single-blind placebo run-in period, patients were randomised to receive
valsartan 160 mg od or amlodipine 5 mg od. At Week 4, HCTZ 12.5 mg
(group V160/HCTZ12.5) and 25 mg (group V160/HCTZ25) were added
to the valsartan groups and in the A10 patients the amlodipine dose was
force-titrated to 10 mg od.
All treatments reduced BP as well as night-time and daytime BP
levels from baseline. 24-hr SBP was reduced by 15.9 1.0 mmHg
(least-squares mean change SE), 19.3 1.0 mmHg and 16.1 1.1
mmHg in the V160/HCTZ12.5, V160/HCTZ25 and A10 groups, re-
spectively and 24-hr DBP was reduced by 9.3 0.6 mmHg, 11.4 0.6
mmHg and 9.6 0.7 mmHg in the three groups. The differences
between the V160/HCTZ25 group and the A10 group were significant
(p0.05) for the changes in 24-hr systolic BP as well as for changes
in daytime systolic BP and night-time diastolic BP. Control rates
defined as ABPM 130/80 mmHg were: 48.4%, 60.8% and 50.9% in
the V160/HCTZ12.5, V160/25 and A10 groups, respectively; the
differences between the V160/HCTZ25 group and the other two
treatment groups were significant at p0.05.
In conclusion, the fixed-dose combination of valsartan 160 mg 
HCTZ 25 mg od is an attractive therapeutic option measured on the
effects on 24-hr ABPM, night-time and daytime BP reduction and control
rates in hypertensive patients at additional cardiovascular risk.
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HOME VERSUS CLINIC BLOOD PRESSURE
MONITORING IN THE ASSESSMENT OF THE
ANTIHYPERTENSIVE EFFICACY OF COMBINATION
PHARMACOTHERAPY
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Association of General Practitioners, ELEGEIA, Greece; Hypertension
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Self-blood pressure monitoring at home (HBP) is regarded as an impor-
tant adjunct to clinic measurements (CBP) in hypertensive patients. This
study compared HBP with CBP measurements in the assessment of the
additional antihypertensive effect of several drugs administered in pa-
tients uncontrolled on antihypertensive drug monotherapy.
Hypertensive patients uncontrolled on diltiazem monotherapy (240 mg
o.d.) were randomized to receive add-on therapy with the thiazide di-
uretic (TZD) chlorthalidone (12.5 mg), the dihydropyridine calcium
antagonist (DCA) felodipine (5 mg), the ACE inhibitor (ACEI) lisinopril
(10 mg), or the angiotensin receptor blocker (ARB) valsartan (80 mg) for
8 weeks. Add-on treatment was doubled if CBP remained uncontrolled
after 4 weeks of randomized combination pharmacotherapy. CBP (trip-
licate measurements) and HBP (3 days, duplicate morning and evening
self-measurements) were measured before randomisation and after 4 and
8 weeks using validated automated oscillometric devices A&D 767.
A total of 185 completed the study (mean age 63.910.6 years, 43%
men). Before randomization average CBP (158.613.1/86.19.4
mmHg, systolic/diastolic) was higher than average HBP (150.313.3/
83.0 8.6 mmHg) (p0.001). After 8 weeks of combination pharmaco-
therapy a significant decline in both CBP and HBP was observed with all
drugs (p0.001, table).
Blood pressure decline achieved by each drug combination (SBP systolic;
DBP diastolic; mmHg)
Added drug N Clinic SBP Home SBP Clinic DBP Home DBP
TZD 51 22.8  13.1 16.0  10.8 8.5  9.2 5.5  7.6
DCA 36 26.6  17.0 20.5  14.0 9.2  8.5 6.3  6.2
ACEI 50 18.8  15.7 16.6  12.0 6.5  10.6 6.5  6.7
ARB 48 20.9  13.8 15.2  10.8 6.7  9.2 4.5  6.3
There was no statistically significant difference in the additive antihy-
pertensive effects of the four drug classes assessed using either CBP or
HBP measurements.
HBP monitoring is a useful alternative to CBP for the assessment of
the additional antihypertensive effect of drugs administered in hyperten-
sive patients uncontrolled on monotherapy.
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AN EFFICACY EVALUATION OF OLMESARTAN
MEDOXOMIL/HYDROCHLOROTHIAZIDE (OM/HCT)
AND AMLODIPINE BESYLATE/BENAZEPRIL
HYDROCHLORIDE (AM/BN)
Albert A. Stone. Medical Affairs, Sankyo Pharma Inc, Fuquay-Varina,
NC.
Most hypertensive patients require more than one agent in order to
achieve adequate blood pressure (BP) control. Fixed-dose combination
antihypertensive treatments such as OM/HCT and AM/BN have advan-
tages over monotherapy including increased efficacy, reduced side effects
and lower costs. The aim of this review is to compare the efficacy of
OM/HCT with AM/BN in similarly designed placebo-controlled factorial
studies. MEDLINE, EMBASE and BIOSIS searches identified 4 ran-
domized, double-blind, placebo-controlled, factorial-design efficacy stud-
ies. One study compared OM/HCT to OM or HCT monotherapy
(Chrysant et al, Am J Hypertens 2004;17:252-9) and 3 studies compared
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